GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Shiller PE Ratio

Synergy Pharmaceuticals (FRA:S90) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synergy Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Synergy Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Shiller PE Ratio Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synergy Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Shiller PE Ratio falls into.



Synergy Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Synergy Pharmaceuticals's E10 for the quarter that ended in Sep. 2018 is calculated as:

For example, Synergy Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2018 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2018 (Change)*Current CPI (Sep. 2018)
=-0.12/106.5067*106.5067
=-0.120

Current CPI (Sep. 2018) = 106.5067.

Synergy Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200812 -0.037 88.697 -0.044
200903 -0.015 89.744 -0.018
200906 -0.021 91.003 -0.025
200909 -0.021 91.120 -0.025
200912 -0.027 91.111 -0.032
201003 -0.022 91.821 -0.026
201006 -0.057 91.962 -0.066
201009 -0.031 92.162 -0.036
201012 -0.060 92.474 -0.069
201103 -0.057 94.283 -0.064
201106 -0.069 95.235 -0.077
201109 -0.007 95.727 -0.008
201112 -0.084 95.213 -0.094
201203 -0.098 96.783 -0.108
201206 -0.135 96.819 -0.149
201209 -0.116 97.633 -0.127
201212 -0.137 96.871 -0.151
201303 -0.201 98.209 -0.218
201306 -0.083 98.518 -0.090
201309 -0.112 98.790 -0.121
201312 -0.161 98.326 -0.174
201403 -0.130 99.695 -0.139
201406 -0.206 100.560 -0.218
201409 -0.186 100.428 -0.197
201412 -0.260 99.070 -0.280
201503 -0.259 99.621 -0.277
201506 -0.303 100.684 -0.321
201509 -0.205 100.392 -0.217
201512 -0.248 99.792 -0.265
201603 -0.458 100.470 -0.486
201606 -0.205 101.688 -0.215
201609 -0.196 101.861 -0.205
201612 -0.294 101.863 -0.307
201703 -0.280 102.862 -0.290
201706 -0.294 103.349 -0.303
201709 -0.185 104.136 -0.189
201712 -0.135 104.011 -0.138
201803 -0.122 105.290 -0.123
201806 -0.103 106.317 -0.103
201809 -0.120 106.507 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synergy Pharmaceuticals  (FRA:S90) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Synergy Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines